Hikma Pharmaceuticals Plc (LON:HIK) has been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is GBX 1,190 ($16.14).
A number of equities analysts recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Hikma Pharmaceuticals from GBX 1,320 ($17.90) to GBX 1,000 ($13.56) and set a “hold” rating on the stock in a research report on Thursday, November 9th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Hikma Pharmaceuticals in a report on Monday. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.85) price target on shares of Hikma Pharmaceuticals in a report on Wednesday, November 15th. Numis Securities raised shares of Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,300 ($17.63) price target on the stock in a report on Thursday, November 9th. Finally, lowered their price target on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.37) to GBX 865 ($11.73) and set a “reduce” rating on the stock in a report on Friday, November 10th.
Shares of Hikma Pharmaceuticals (LON:HIK) opened at GBX 996.80 ($13.52) on Friday. Hikma Pharmaceuticals has a fifty-two week low of GBX 906.50 ($12.29) and a fifty-two week high of GBX 2,346 ($31.81). The firm has a market cap of $2,400.00 and a price-to-earnings ratio of 1,993.60.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.